Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen resolved to convene an Extraordinary General Meeting of Shareholders on December 26, 2024, at Daejeon Convention Center to vote on proposed amendments to the Articles of Incorporation. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Specific Amendments…

Read More “[Disclosure] ALTEOGEN (196170) – Board Resolution on Convening Extraordinary General Shareholders Meeting / 2024-11-18” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its pharmaceutical contract manufacturing agreement with F.Hoffmann-La Roche Ltd, extending the contract end date from December 31, 2024, to December 31, 2025, upon the customer’s request. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2024-11-18” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its pharmaceutical contract manufacturing agreement with F.Hoffmann-La Roche Ltd, increasing the contract amount to approx. KRW 241.4B (USD 219,380,393) and extending the contract end date to December 31, 2028. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2024-11-18” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen issued a corrective disclosure to amend and postpone the merger schedule—including the EGM date, creditor objection period, merger date (December 31, 2024), and registration date—for the absorption merger between its subsidiaries Altos Biologics and Alteogen Healthcare. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s…

Read More “[Disclosure] ALTEOGEN (196170) – (Correction) Decision on Merger / 2024-11-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen issued a corrective disclosure to adjust the scheduled acquisition date (December 31, 2024) and board resolution date (November 14, 2024) regarding its share acquisition in subsidiary Altos Biologics, following a schedule change in the intra-group merger. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s…

Read More “[Disclosure] ALTEOGEN (196170) – (Correction) Decision on Acquisition of Shares and Investment Certificates of Other Corporations / 2024-11-14” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion issued a correction disclosure regarding its Plant 3 construction, adjusting the final investment amount from KRW 274 billion to KRW 256.204 billion following the completion of construction settlement. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Plant…

Read More “[Disclosure] Celltrion (068270) – New Facility Investment (Correction) / 2024-11-12” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen executed an exclusive license agreement with Daiichi Sankyo for the development and commercialization of a subcutaneous (SC) formulation of the ADC therapy Enhertu® using ALT-B4 technology, featuring an upfront payment of approx. KRW 28.0B and milestones up to approx. KRW 391.7B. 📊 [Key Disclosure Details…

Read More “[Disclosure] ALTEOGEN (196170) – Execution of Exclusive License Agreement (ALT-B4 Technology) / 2024-11-08” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen will hold an in-person Investor Relations (IR) conference for domestic and foreign securities analysts in Yeouido on November 12, 2024, to enhance corporate understanding and deliver accurate information. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying IR Presentation…

Read More “[Disclosure] ALTEOGEN (196170) – Holding of Investor Relations (IR) Session / 2024-11-08” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported its provisional Q3 2024 consolidated financial results, recording revenue of approximately KRW 881.9B and operating profit of approximately KRW 207.7B, representing a 186.51% QoQ increase in operating profit. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of…

Read More “[Disclosure] Celltrion (068270) – Provisional Sales Results (Consolidated Financial Statements) / 2024-11-08” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported its provisional Q3 2024 separate financial results, recording revenue of approximately KRW 1.04T and operating profit of approximately KRW 461.7B, representing a 47.47% QoQ increase in operating profit. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Comparison Between…

Read More “[Disclosure] Celltrion (068270) – Provisional Sales Results / 2024-11-08” »